Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/23756
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVerma, Indu-
dc.contributor.authorPandey, Rajesh-
dc.contributor.authorKhuller, G K-
dc.date.accessioned2013-11-19T06:25:43Z-
dc.date.available2013-11-19T06:25:43Z-
dc.date.issued2004-10-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/23756-
dc.description949-954en_US
dc.description.abstractMycobacteria are intracellular pathogens that invade and reside inside the macrophages. Recent advances in controlled delivery systems for vaccines such as liposomes have sparked a renewed interest in their potential application for the prevention of mycobacterial infections. The versatility of liposomes in the incorporation of hydrophilic/hydrophobic components, their non-toxic nature, biodegradability, biocompatibility, adjuvanticity, induction of cellular immunity, property of sustained release and prompt uptake by macrophages, makes them attractive candidates for the delivery of antigens. This review focuses on liposome research in the area of mycobacterial diseases and highlights how the various mycobacterial components may be exploited as powerful antigens with liposomes as adjuvants.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJEB Vol.42(10) [October 2004]en_US
dc.subjectLiposomeen_US
dc.subjectAntigenen_US
dc.subjectAdjuvanten_US
dc.subjectMacrophageen_US
dc.subjectTuberculosisen_US
dc.titleLiposomes as adjuvant for anti-mycobacterial vaccine developmenten_US
dc.typeArticleen_US
Appears in Collections:IJEB Vol.42(10) [October 2004]

Files in This Item:
File Description SizeFormat 
IJEB 42(10) 949-954.pdf1.64 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.